

Abstract Submission –Terms & Conditions

- 1) Authors can modify the author's information, topic, and core data of their abstract directly on the submission system until the deadline given. Please be aware that there will be no extension possible.
- 2) By submitting this abstract, I understand that my abstract, including names, is stored electronically, and may be published by the Organising Committee on the DHM Hybrid 2023 website, EAACI Content Platform and the DHM Hybrid 2023 Digital platform. Failure to present the abstract at the event will result in exclusion from online publishing on the DHM Hybrid 2023 website, EAACI Content Platform and the DHM Hybrid 2023 Digital platform.
- 3) By submitting this abstract, I understand that my personal data will be stored and shared with EAACI, CYIM, the EAACI Committees, and abstract reviewers involved in the abstract selection for the DHM Hybrid 2023. Transfer of personal data to contractors as well as EAACI related scientific organisations may occur for production, promotion, and dissemination of congress content.
- 4) By submitting this abstract, I agree to transfer the copyright to EAACI.
- 5) Trade names are not allowed, as well as copyright and trademark symbols. Non-proprietary (generic) names of drugs, written in lower case, are required the first time a drug is mentioned in the text. References, credits, or the authors' academic degrees or grant support are not to be included in the abstract. Standard abbreviations may be employed in the text. Place special or unusual abbreviations in parentheses after the full wording the first time it appears in the body of the text. Company names and logos are not allowed in the title but can be named in the authors' affiliation.
- 6) All abstracts will be blinded for review by a minimum of 3 members of the abstract review committee. All the reviewers have been selected by the Scientific Programme Committee to review abstracts in their category that best fits their expertise.

EAACI aims for good quality of science without compromising scientific integrity.

The abstract reviewers are required to identify abstracts pertaining to commercial promotion of a proprietary product, data originating from the same study across several abstracts in order to notify the Scientific Programme Committee.

Please note that the final decisions regarding the allocation and the type of presentation of the submitted abstract will be made by the Scientific Programme Committee. No rescheduling or changes by the submitters will be possible once the abstract deadline is closed.

- 7) The presenting author receives all correspondence concerning the abstract and is responsible for informing all co-authors of the status of the abstract. The presenting author of an abstract must register for the meeting by the given deadline. If EAACI does not receive your registration and payment by the deadline, your abstract will be removed from the programme.
- 8) Consent for publication of individual patient data - **applies to abstracts with identifiable patient information.**

For the publication of an abstract that contains identifiable information about patients it is necessary that patients have given consent for the research to be published. For all abstracts that include identifiable patient details (e.g., gender, age, illness, location) or images, written informed consent for the publication of these must be obtained from the patient (or their parent or legal guardian).

By agreeing to these terms, I confirm that:

- a) written informed consent for publication of these clinical details and/or clinical images included in my abstract presentation was obtained from the patient/parent/guardian/relative of the patient. (Please include an explanatory statement in your abstract text).
- b) The final decision on whether consent to publish is required or not lies with EAACI.
- 9) Duplication of publications

Unpublished abstracts that have been presented at a different scientific meeting within a 12-month period prior to DHM Hybrid 2023, provided they contain updated/additional data, can be submitted, and will be considered for presentation. Abstracts submitted for publication or to a scientific meeting, but are pending acceptance, can be submitted without restrictions. However, once the abstract has been accepted by EAACI it is automatically subject to the EAACI [embargo guidelines](#).

- 10) Declaration of Conflict of Interest

EAACI is committed to ensuring the integrity of its scientific, educational, and research programmes. Abstract submission requires disclosure of any financial or other interest that might be construed as resulting in an actual, potential, or apparent conflict. The submitter is responsible for obtaining disclosure information from all co-authors, to be entered in the author section of the submission page.

Date: October 2022